Danaher Corporation $DHR Shares Newly Purchased by Cantor Fitzgerald Investment Advisors L.P.

Posted by George Bondi on Oct 16th, 2026

Cantor Fitzgerald Investment Advisors L.P. purchased a new stake in Danaher Corporation (NYSE:DHR – Free Report) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 4,500 shares of the conglomerate’s stock, valued at approximately $997,000.

A number of other hedge funds also recently made changes to their positions in the business. BlackRock Inc. bought a new position in Danaher in the 2nd quarter worth approximately $10,492,520,000. Wellington Management Group LLP raised its stake in Danaher by 10.4% during the 2nd quarter. Wellington Management Group LLP now owns 16,316,834 shares of the conglomerate’s stock valued at $3,108,031,000 after acquiring an additional 1,542,310 shares in the last quarter. Jupiter Topco LLC bought a new stake in Danaher during the 2nd quarter valued at $1,456,317,000. Generation Investment Management LLP bought a new stake in Danaher during the 2nd quarter valued at $1,287,949,000. Finally, Bank of America Corp DE acquired a new position in Danaher during the 2nd quarter worth $993,846,000. Institutional investors own 79.05% of the company’s stock.

Danaher Price Performance

Shares of Danaher stock opened at $231.52 on Friday. Danaher Corporation has a 52 week low of $160.93 and a 52 week high of $242.80. The company has a current ratio of 1.65, a quick ratio of 1.25 and a debt-to-equity ratio of 0.48. The stock has a market cap of $162.76 billion, a PE ratio of 41.12, a price-to-earnings-growth ratio of 2.82 and a beta of 0.76. The company’s 50-day moving average price is $213.55 and its two-hundred day moving average price is $195.74.

Danaher (NYSE:DHR – Get Free Report) last posted its quarterly earnings data on Monday, July 20th. The conglomerate reported $1.94 earnings per share for the quarter, beating the consensus estimate of $1.85 by $0.09. Danaher had a net margin of 15.95% and a return on equity of 11.04%. The company had revenue of $6.26 billion during the quarter, compared to analyst estimates of $6.12 billion. During the same quarter last year, the firm posted $0.77 EPS. The business’s revenue for the quarter was up 5.5% on a year-over-year basis. As a group, sell-side analysts anticipate that Danaher Corporation will post 8.53 EPS for the current fiscal year.

Danaher Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be issued a dividend of $0.40 per share. This represents a $1.60 dividend on an annualized basis and a yield of 0.7%. The ex-dividend date is Wednesday, September 30th. Danaher’s dividend payout ratio (DPR) is presently 28.42%.

Wall Street Analyst Weigh In

DHR has been the subject of several recent analyst reports. The Goldman Sachs Group increased their price target on Danaher from $210.00 to $250.00 and gave the stock a “buy” rating in a research note on Monday, September 21st. TD Cowen lifted their price objective on shares of Danaher from $236.00 to $255.00 and gave the company a “buy” rating in a research note on Tuesday. Guggenheim upped their price objective on shares of Danaher from $200.00 to $250.00 and gave the stock a “buy” rating in a report on Thursday, October 1st. Weiss Ratings raised shares of Danaher from a “hold (c-)” rating to a “hold (c)” rating in a report on Wednesday, September 16th. Finally, Evercore reiterated an “outperform” rating and issued a $230.00 target price on shares of Danaher in a research report on Monday, July 6th. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Danaher has a consensus rating of “Moderate Buy” and an average target price of $235.41.

View Our Latest Research Report on Danaher

Danaher News Roundup

Here are the key news stories impacting Danaher this week:

Positive Sentiment: Danaher and NVIDIA announced an AI collaboration to combine Danaher’s scientific instruments, laboratory workflows, automation technology and software with NVIDIA’s accelerated computing and AI capabilities. The partnership is intended to advance autonomous science and speed drug discovery and other laboratory research. Danaher Collaborates with NVIDIA to Advance Autonomous Science
Positive Sentiment: Danaher is also preparing to launch its first AI-powered autonomous laboratory, targeted to operate at commercial scale in early 2027. The initiative could support longer-term growth in laboratory automation and strengthen the company’s position in AI-enabled life-science research. How to Invest in AI Drug Discovery
Positive Sentiment: Multiple Zacks reports say Danaher has a favorable combination of earnings-estimate trends and Earnings ESP, suggesting potential for the company to exceed consensus estimates in its next quarterly report. Danaher has also recently demonstrated earnings momentum, with its latest reported quarter exceeding both EPS and revenue expectations. Will Danaher Beat Estimates Again in Its Next Earnings Report?
Neutral Sentiment: Danaher is projected to announce earnings on Wednesday. Investors will be watching revenue growth, management’s outlook and whether diagnostics and life-sciences demand support the anticipated improvement in earnings. Danaher Projected to Announce Earnings

About Danaher

(Free Report)

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.

The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.